KIT and cancer: This suggests that the use of combination therapies involving novel anti-KIT ADCs in conjunction with standard chemotherapeutic agents, TK inhibitors, or other targeted agents, should be considered a strategy to enhance the efficacy of anti-KIT ADCs used as a monotherapy for different cancer types.